Q1 FY27 results: revenue up 23% YoY, PAT up 36%, 200% dividend recommended

Revenue growth above 20%Profit growth above 25%Results restatedResults View source PDF Explain this filing

VIJAYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹1346.00

prior close

₹1384.70

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.0%+0.2% vs market

Healthcare Service Provider peers, median of 26sector+0.3%-0.1% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Smallcap 250 and 0.1 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.5

10m

+1.0

15m

+0.9

30m

+1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2-0.0+0.2+0.3-0.1

Next day

+3.7-0.1+3.8+0.7+3.0

+6.8+0.1+6.6+0.7+6.1

+13.1-0.1+13.3-0.0+13.2

+9.9+0.0+9.8+0.4+9.5

+9.0-0.4+9.4-1.7+10.7

+10.8-0.1+10.9-0.9+11.8

15d

+7.8+0.7+7.1+0.0+7.8

+11.2+0.7+10.5+1.8+9.5

+8.1-2.4+10.5-2.9+11.0

—————

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone revenue from operations grew 23.2% YoY to Rs 21,853.71 lakhs. PAT grew 36% to Rs 5,314.76 lakhs. EPS at Rs 5.17 vs Rs 3.80. Consolidated revenue up 22.8% to Rs 23,098.19 lakhs, PAT up 37.6% to Rs 5,310.11 lakhs. 200% dividend (Rs 2 per share) recommended for FY26. Results restated due to common control acquisition of Medinova Millennium MRI Services LLP. Auditors BSR issued an unmodified limited review report.

Likely market impact

Strong quarter with double-digit growth in revenue and profit plus a 200% dividend. Positive for shareholders; restated comparables reflect internal restructuring.